NICE releases draft guidance approving a new treatment for advanced bowel cancer patients
Thursday 29 August 2024
The National Institute for Health and Care Excellence (NICE) has published draft guidance approving the use of trifluridine-tipiracil (Lonsurf) with bevacizumab (Avastin) for eligible patients living in England and Wales.
The guidance recommends that Lonsurf, given together with Avastin, should be available from the NHS in England and Wales to patients who have advanced bowel cancer and have already received two previous cancer treatment regimens.
The decision stands as draft guidance for the next 15 days to allow for appeals or edits and the final recommendation will be published on Wednesday 25 September. This is standard practice before final guidance is published by NICE.
We provided advice to NICE on the benefits of having access to this drug combination for advanced bowel cancer patients, along with other patient groups and healthcare professionals. We'll continue to advocate for greater patient choice in bowel cancer treatments
The decision comes after the Scottish Medicines Consortium (SMC) approved the drug for advanced bowel cancer patients in Scotland earlier this month.
- Learn more about advanced bowel cancer
- Learn more about our campaigning work
- Access our support